Pinto, L F <br/><br/>
Rituximab induces a rapid and sustained remission in Colombian patients with severe and refractory systemic lupus erythematosus.  [electronic resource] 

 -  Lupus  Oct 2011 
 - 1219-26 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1477-0962 
<br/><br/><label>Standard No.: </label>10.1177/0961203311409273  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal, Murine-Derived--adverse effects<br/>Cohort Studies<br/>Colombia<br/>Creatinine--blood<br/>Female<br/>Glucocorticoids--therapeutic use<br/>Humans<br/>Immunosuppressive Agents--therapeutic use<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Lupus Nephritis--therapy<br/>Male<br/>Prospective Studies<br/>Proteinuria--therapy<br/>Remission Induction<br/>Rituximab<br/>Treatment Failure<br/>Treatment Outcome<br/>Young Adult